Sponsoring Agency HHS
    POP 9/24/12 - 9/23/17 (4 years)


The National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Prevention (DCP), Phase I/II Cancer Prevention Clinical Trials Program will provide essential clinical trials infrastructure and laboratory support: (1) To efficiently design and conduct early phase clinical trials of cancer preventive agents of various classes; (2) To characterize the biological effects of new cancer preventive agents on their defined molecular targets as well as on multiple endpoints associated with carcinogenesis and correlate these effects with clinically relevant endpoints; and (3) To develop scientific insights into the mechanisms of cancer prevention by the agents examined and to continue to develop novel potential markers as determinants of response.

  • $24m Aggregate Dollars Obligated
  • $24m Aggregate Base & Exercised Options
  • $38.1m Aggregate Base & All Options (Ceiling)

Market Stats Related Contracts